Fast Market Research announces the availability of the new Business Monitor International report, "Kuwait Pharmaceuticals & Healthcare Report Q1 2016", on their comprehensive research portal

Boston, MA -- (SBWire) -- 12/08/2015 --Kuwait's pharmaceutical sector will remain insulated from the impact of lower oil prices given the country's strong fiscal buffers. Risks to our outlook include increasing generic penetration as health insurance coverage increases.

Headline Expenditure Projections

Pharmaceuticals: From KWD287mn (USD1.01bn) in 2014 to KWD300mn (USD1.01bn) in 2015; +4.7% in local currency terms and +0.6% in US dollar terms. Forecast unchanged from Q415.
Healthcare: From KWD1.53bn (USD5.38bn) in 2014 to KWD1.64bn (USD5.55bn) in 2015; +7.3% in local currency terms and +3.1% in US dollar terms. Forecast in line with Q 4 15.

Risk/Reward Index

In our Q116 Pharmaceutical Risk/Reward Index Kuwait scores 52.9 out of 100. Falling from a Q415 score of 53.7, the country has maintained its position as the sixth most attractive market in the region. The burden of diabetes will continue to expand in the region as the population ages and adopts increasingly sedentary lifestyles. Increasing insurance coverage and rising income levels will lead to greater spending on diabetes, and commercial opportunities will be sought by multinational pharmaceutical companies, health insurers and providers.

Get More Details on this Report and a Full Table of Contents at Kuwait Pharmaceuticals & Healthcare Report Q1 2016

The Kuwait Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Kuwait Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Kuwait pharmaceutical and healthcare industry.

Key Benefits

-Benchmark BMI's pharmaceutical and healthcare market forecasts for Kuwait, to test other views - a key input for successful budgeting and strategic business planning in the Kuwaiti pharmaceutical and healthcare market.
-Target business opportunities and risks in the Kuwaiti pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Kuwait.
-Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI?s forecast analysis, and taken together with BMI?s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

-Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ?000 population).
-Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
-Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
-Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
-OTC Drug Market: OTC sales (USDbn & % of total sales).
-Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI?s Pharmaceuticals and Healthcare Risk Reward Index

BMI?s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market?s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Healthcare research reports at Fast Market Research

You may also be interested in these related reports:

-Kenya Pharmaceuticals & Healthcare Report Q1 2016
-Ukraine Pharmaceuticals & Healthcare Report Q1 2016
-Thailand Pharmaceuticals & Healthcare Report Q1 2016
-Pakistan Pharmaceuticals & Healthcare Report Q1 2016
-Argentina Pharmaceuticals & Healthcare Report Q1 2016